Perioperative Treatment of Patients with Rheumatoid Arthritis

Journal of the American Academy of Orthopaedic Surgeons

Volumn 23, Issue 9, 2015, Pages e38-e48

  Saleh, Khaled J ^a   Kurdi, Alexander J ^a   El Othmani, Mouhanad M ^a   Voss, Benjamin A ^a   Tzeng, Tony H ^a   Saleh, Jasmine ^b   Lane, Joseph M ^c   Mihalko, William M ^d  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HOSPITAL FOR SPECIAL SURGERY   (United States)

^d Campbell Clinic Memphis   (United States)

Author keywords

disease modifying antirheumatic drugs; preoperative clearance; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT;

ARTHRITIS, RHEUMATOID; HUMAN; MULTIMODALITY CANCER THERAPY; ORTHOPEDIC SURGERY; PREOPERATIVE PERIOD; PROCEDURES; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COMBINED MODALITY THERAPY; HUMANS; ORTHOPEDIC PROCEDURES; PREOPERATIVE PERIOD; TREATMENT OUTCOME;

EID: 84940029117     PISSN: 1067151X     EISSN: None     Source Type: Journal    
DOI: 10.5435/JAAOS-D-15-00014     Document Type: Conference Paper

References (123)

1. Aksu K, Donmez A, Keser G: Inflammation-induced thrombosis: Mechanisms, disease associations and management. Curr Pharm Des 2012;18 (11):1478-1493.
2. Myasoedova E, Davis JM III, Crowson CS, Gabriel SE: Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010;12(5):379-385.
3. Firestein GS: Evolving concepts of rheumatoid arthritis. Nature 2003;423 (6937):356-361.
4. Gullick NJ, Scott DL: Co-morbidities in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2011;25(4): 469-483.
5. Rossini M, Rossi E, Bernardi D, et al: Prevalence and incidence of rheumatoid arthritis in Italy. Rheumatol Int 2014;34 (5):659-664.
6. Alamanos Y, Voulgari PV, Drosos AA: Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review. Semin Arthritis Rheum 2006;36(3):182-188.
7. Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L; SERAP Study Group: The incidence of rheumatoid arthritis in Spain: Results from a nationwide primary care registry. Rheumatology (Oxford) 2008;47(7): 1088-1092.
8. McInnes IB, Schett G: The pathogenesis of rheumatoid arthritis. N Engl J Med 2011; 365(23):2205-2219.
9. Masuda H, Miyazaki T, Shimada K, et al: Disease duration and severity impacts on long-term cardiovascular events in Japanese patients with rheumatoid arthritis. J Cardiol 2014;64(5):366-370.
10. Ajeganova S, Andersson ML, Frostegård J, Hafström I: Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: A 10-year observational cohort study. J Rheumatol 2013;40(12):1958-1966.
11. Avouac J, Meune C, Chenevier-Gobeaux C, et al: Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J Rheumatol 2014;41(2):248-255.
12. Naz SM, Symmons DP: Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007;21(5): 871-883.
13. Louie GH, Ward MM: Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983-2007. Ann Rheum Dis 2010;69(5):868-871.
14. Carmona L, Cross M, Williams B, Lassere M, March L: Rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010;24(6):733-745.
15. Howe CR, Gardner GC, Kadel NJ: Perioperative medication management for the patient with rheumatoid arthritis. J Am Acad Orthop Surg 2006;14(9):544-551.
16. Momohara S, Tanaka S, Nakamura H, et al: Recent trends in orthopedic surgery performed in Japan for rheumatoid arthritis. Mod Rheumatol 2011;21(4): 337-342.
17. Härle P, Straub RH, Fleck M: Perioperative management of immunosuppression in rheumatic diseases: What to do? Rheumatol Int 2010;30(8):999-1004.
18. Stundner O, Danninger T, Chiu YL, et al: Rheumatoid arthritis vs osteoarthritis in patients receiving total knee arthroplasty: Perioperative outcomes. J Arthroplasty 2014;29(2):308-313.
19. Lee JK, Choi CH: Total knee arthroplasty in rheumatoid arthritis. Knee Surg Relat Res 2012;24(1):1-6.
20. Simmen BR, Bogoch ER, Goldhahn J: Surgery insight: Orthopedic treatment options in rheumatoid arthritis. Nat Clin Pract Rheumatol 2008;4(5):266-273.
21. Rheumatic diseases: Surgical treatment. A systematic literature review by SBU: The Swedish Council on Technology Assessment in Health Care. Acta Orthop Scand Suppl 2000;294:1-88.
22. Nelissen RG: The impact of total joint replacement in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2003;17(5): 831-846.
23. Wilkinson JM, Stanley D, Getty CJ: Surgical management of the rheumatoid patient. Curr Orthop 2004;18(5): 357-370.
24. Clement ND, Breusch SJ, Biant LC: Lower limb joint replacement in rheumatoid arthritis. J Orthop Surg Res 2012;7:27.
25. Goodman SM, Figgie M: Lower extremity arthroplasty in patients with inflammatory arthritis: Preoperative and perioperative management. J Am Acad Orthop Surg 2013;21(6):355-363.
26. Stockley I, Betts RP, Getty CJ, Rowley DI, Duckworth T: A prospective study of forefoot arthroplasty. Clin Orthop Relat Res 1989;248:213-218.
27. Meding JB, Keating EM, Ritter MA, Faris PM, Berend ME, Malinzak RA: The planovalgus foot: A harbinger of failure of posterior cruciate-retaining total knee replacement. J Bone Joint Surg Am 2005; 87(suppl 2):59-62.
28. Keenan MA, Peabody TD, Gronley JK, Perry J: Valgus deformities of the feet and characteristics of gait in patients who have rheumatoid arthritis. J Bone Joint Surg Am 1991;73(2):237-247.
29. Papp SR, Athwal GS, Pichora DR: The rheumatoid wrist. J Am Acad Orthop Surg 2006;14(2):65-77.
30. Stanley J: The rheumatoid wrist. Curr Orthop 2001;15(5):329-337.
31. Connor J, Nalebuff EA: Current recommendations for surgery of the rheumatoid hand and wrist. Curr Opin Rheumatol 1995;7(2):120-124.
32. Herren DB, Ishikawa H: Partial arthrodesis for the rheumatoid wrist. Hand Clin 2005;21(4):545-552.
33. Ovesen J, Olsen BS, Johannsen HV, Søjbjerg JO: Capitellocondylar total elbow replacement in late-stage rheumatoid arthritis. J Shoulder Elbow Surg 2005;14(4):414-420.
34. Ewald FC, Simmons ED Jr, Sullivan JA, et al: Capitellocondylar total elbow replacement in rheumatoid arthritis: Long-term results. J Bone Joint Surg Am 1993;75(4):498-507.
35. Neer CS II, Kirby RM: Revision of humeral head and total shoulder arthroplasties. Clin Orthop Relat Res 1982;170:189-195.
36. Bacani AK, Gabriel SE, Crowson CS, Heit JA,Matteson EL: Noncardiac vascular disease in rheumatoid arthritis: Increase in venous thromboembolic events? Arthritis Rheum 2012;64(1):53-61.
37. Nicola PJ, Maradit-Kremers H, Roger VL, et al: The risk of congestive heart failure in rheumatoid arthritis: A population-based study over 46 years. Arthritis Rheum 2005;52(2):412-420.
38. Maradit-Kremers H, Crowson CS, Nicola PJ, et al: Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: A populationbased cohort study. Arthritis Rheum 2005;52(2):402-411.
39. Avinã-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D: Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Rheum 2008;59(12): 1690-1697.
40. Minaur NJ, Jacoby RK, Cosh JA, Taylor G, Rasker JJ: Outcome after 40 years with rheumatoid arthritis: A prospective study of function, disease activity, and mortality. J Rheumatol Suppl 2004;69:3-8.
41. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A: Death rates and causes of death in patients with rheumatoid arthritis: A population-based study. Scand J Rheumatol 2004;33(4):221-227.
42. Brown KK: Rheumatoid lung disease. Proc Am Thorac Soc 2007;4(5):443-448.
43. Bongartz T, Nannini C, Medina-Velasquez YF, et al: Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study. Arthritis Rheum 2010;62(6): 1583-1591.
44. Choi SM, Lee J, Park YS, et al: Postoperative pulmonary complications after surgery in patients with interstitial lung disease. Respiration 2014;87(4): 287-293.
45. da Côrte FC, Neves N: Cervical spine instability in rheumatoid arthritis. Eur J Orthop Surg Traumatol 2014;24 (suppl 1):S83-S91.
46. Collins DN, Barnes CL, FitzRandolph RL: Cervical spine instability in rheumatoid patients having total hip or knee arthroplasty. Clin Orthop Relat Res 1991; 272:127-135.
47. Neva MH, Häkkinen A, Mäkinen H, Hannonen P, Kauppi M, Sokka T: High prevalence of asymptomatic cervical spine subluxation in patients with rheumatoid arthritis waiting for orthopaedic surgery. Ann Rheum Dis 2006;65(7):884-888.
48. Danoff JR, Moss G, Liabaud B, Geller JA: Total knee arthroplasty considerations in rheumatoid arthritis. Autoimmune Dis 2013;2013:185340.
49. Neva MH, Myllykangas-Luosujärvi R, Kautiainen H, Kauppi M: Mortality associated with cervical spine disorders: A population-based study of 1666 patients with rheumatoid arthritis who died in Finland in 1989. Rheumatology (Oxford) 2001;40(2):123-127.
50. Weinblatt ME, Maier AL, Fraser PA, Coblyn JS: Long-term prospective study of methotrexate in rheumatoid arthritis: Conclusion after 132 months of therapy. J Rheumatol 1998;25(2):238-242.
51. Wessels JA, Huizinga TW, Guchelaar HJ: Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2008;47(3):249-255.
52. Revu S, Neregård P, af Klint E, Korotkova M, Catrina AI: Synovial membrane immunohistology in earlyuntreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate. Arthritis Res Ther 2013;15(6):R205.
53. Grennan DM, Gray J, Loudon J, Fear S: Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis 2001;60(3): 214-217.
54. Murata K, Yasuda T, Ito H, Yoshida M, Shimizu M, Nakamura T: Lack of increase in postoperative complications with lowdose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol 2006;16(1):14-19.
55. Pieringer H, Stuby U, Biesenbach G: The place of methotrexate perioperatively in elective orthopedic surgeries in patients with rheumatoid arthritis. Clin Rheumatol 2008;27(10):1217-1220.
56. Sreekumar R, Gray J, Kay P, Grennan DM: Methotrexate and postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery: A ten year follow-up. Acta Orthop Belg 2011;77(6): 823-826.
57. Minaur NJ, Jefferiss C, Bhalla AK, Beresford JN: Methotrexate in the treatment of rheumatoid arthritis: I. In vitro effects on cells of the osteoblast lineage. Rheumatology (Oxford) 2002;41 (7):735-740.
58. Minaur NJ, Kounali D, Vedi S, Compston JE, Beresford JN, Bhalla AK: Methotrexate in the treatment of rheumatoid arthritis: II. In vivo effects on bone mineral density. Rheumatology (Oxford) 2002;41(7):741-749.
59. Uehara R, Suzuki Y, Ichikawa Y: Methotrexate (MTX) inhibits osteoblastic differentiation in vitro: Possible mechanism of MTX osteopathy. J Rheumatol 2001;28(2):251-256.
60. Annussek T, Kleinheinz J, Thomas S, Joos U, Wermker K: Short time administration of antirheumatic drugs: Methotrexate as a strong inhibitor of osteoblast's proliferation in vitro. Head Face Med 2012;8:26.
61. Morgacheva O, Furst DE: Use of MTX in the elderly and in patients with compromised renal function. Clin Exp Rheumatol 2010;28(5 suppl 61):S85-S94.
62. Rosandich PA, Kelley JT III, Conn DL: Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers. Curr Opin Rheumatol 2004;16(3):192-198.
63. Kremer JM, Rynes RI, Bartholomew LE: Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy: Double-blind study. Am J Med 1987;82(4):781-786.
64. Kalden JR, Schattenkirchner M, Sörensen H, et al: The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: A five-year followup study. Arthritis Rheum 2003;48(6): 1513-1520.
65. Fuerst M, Möhl H, Baumgärtel K, Rüther W: Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int 2006;26(12):1138-1142.
66. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344(12): 907-916.
67. Maini RN, Breedveld FC, Kalden JR, et al: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41(9):1552-1563.
68. Chen YF, Jobanputra P, Barton P, et al: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10(42):iii-iv, xi-xiii, 1-229.
69. Furst DE, Keystone EC, So AK, et al: Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72(suppl 2):ii2-ii34.
70. Finckh A, Choi HK, Wolfe F: Progression of radiographic joint damage in different eras: Trends towards milder disease in rheumatoid arthritis are attributable to improved treatment. Ann Rheum Dis 2006;65(9):1192-1197.
71. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295(19):2275-2285.
72. Bernatsky S, Habel Y, Rahme E: Observational studies of infections in rheumatoid arthritis: A meta-analysis of tumor necrosis factor antagonists. J Rheumatol 2010;37(5):928-931.
73. Giles JT, Bartlett SJ, Gelber AC, et al: Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55(2): 333-337.
74. Tubach F, Salmon D, Ravaud P, et al: Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60(7):1884-1894.
75. Dixon WG, Hyrich KL, Watson KD, et al; BSRBR Control Centre Consortium; BSR Biologics Register: Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69(3):522-528.
76. Dao KH, Herbert M, Habal N, Cush JJ: Nonserious infections: Should there be cause for serious concerns? Rheum Dis Clin North Am 2012;38(4):707-725.
77. Bibbo C, Goldberg JW: Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25(5):331-335.
78. Galloway JB, Hyrich KL, Mercer LK, et al; BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register: Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: Updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50(1):124-131.
79. Ruyssen-Witrand A, Gossec L, Salliot C, et al: Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007;25(3):430-436.
80. Scherrer CB, Mannion AF, Kyburz D, Vogt M, Kramers-de Quervain IA: Infection risk after orthopedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs. Arthritis Care Res (Hoboken) 2013;65(12):2032-2040.
81. Strand V, Smolen JS, van Vollenhoven RF, et al: Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: Analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011;70(6):996-1002.
82. Mooney DP, O'Reilly M, Gamelli RL: Tumor necrosis factor and wound healing. Ann Surg 1990;211(2):124-129.
83. Goh L, Jewell T, Laversuch C, Samanta A: Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int 2012;32(1):5-13.
84. Nannini C, Medina-Velasquez YF, Achenbach SJ, et al: Incidence and mortality of obstructive lung disease in rheumatoid arthritis: A population-based study. Arthritis Care Res (Hoboken) 2013;65(8):1243-1250.
85. Momohara S,Hashimoto J, TsuboiH, et al: Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: Results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol 2013;23(3):440-449.
86. Detert J: Early use of biological agents after first DMARD in rheumatoid arthritis: Yes [German]. Dtsch Med Wochenschr 2013;138(37):1850.
87. Edwards CK III, Green JS, Volk HD, et al: Combined anti-tumor necrosis factor-a therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone. Front Immunol 2012;3:366.
88. Detert J, Bastian H, Listing J, et al: Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD. An investigator-initiated study. Ann Rheum Dis 2013;72(6):844-850.
89. Genovese MC, Cohen S, Moreland L, et al; 20000223 Study Group: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50(5):1412-1419.
90. Kirwan JR; The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group: The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333(3):142-146.
91. Chmell MJ, Scott RD: Total knee arthroplasty in patients with rheumatoid arthritis: An overview. Clin Orthop Relat Res 1999;366:54-60.
92. Luessenhop CP, Higgins LD, Brause BD, Ranawat CS: Multiple prosthetic infections after total joint arthroplasty: Risk factor analysis. J Arthroplasty 1996;11(7):862-868.
93. Anstead GM: Steroids, retinoids, and wound healing. Adv Wound Care 1998; 11(6):277-285.
94. Pieringer H, Stuby U, Biesenbach G: Patients with rheumatoid arthritis undergoing surgery: How should we deal with antirheumatic treatment? Semin Arthritis Rheum 2007;36(5):278-286.
95. Saag KG, Shane E, Boonen S, et al: Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357(20):2028-2039.
96. Saag KG, Zanchetta JR, Devogelaer JP, et al: Effects of teriparatide versus alendronate for treating glucocorticoidinduced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60 (11):3346-3355.
97. Shaw M, Mandell BF: Perioperative management of selected problems in patients with rheumatic diseases. Rheum Dis ClinNorthAm 1999;25(3):623-638, ix.
98. Scott DL, Wolfe F, Huizinga TW: Rheumatoid arthritis. Lancet 2010;376 (9746):1094-1108.
99. SchairerWW, Vail TP, Bozic KJ: What are the rates and causes of hospital readmission after total knee arthroplasty? Clin Orthop Relat Res 2014;472(1):181-187.
100. Campbell CL, Smyth S, Montalescot G, Steinhubl SR: Aspirin dose for the prevention of cardiovascular disease: A systematic review. JAMA 2007;297(18): 2018-2024.
101. Lack WD, Fredericks D, Petersen E, et al: Effect of aspirin on bone healing in a rabbit ulnar osteotomy model. J Bone Joint Surg Am 2013;95(6):488-496.
102. Burch JW, Stanford N, Majerus PW: Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978;61(2):314-319.
103. Patrono C, Ciabattoni G, Patrignani P, et al: Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72(6):1177-1184.
104. Bradlow BA, Chetty N: Dosage frequency for suppression of platelet function by low dose aspirin therapy. Thromb Res 1982; 27(1):99-110.
105. Jimenez AH, Stubbs ME, Tofler GH, Winther K, Williams GH, Muller JE: Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 1992;69(3):258-262.
106. Devereaux PJ, Mrkobrada M, Sessler DI, et al; POISE-2 Investigators: Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014;370(16):1494-1503.
107. Manning BJ, O'Brien N, Aravindan S, Cahill RA, McGreal G, Redmond HP: The effect of aspirin on blood loss and transfusion requirements in patients with femoral neck fractures. Injury 2004;35(2):121-124.
108. Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 1998;351(9098):233-241.
109. Samama CM, Bastien O, Forestier F, et al; French Society of Anesthesiology and Intensive Care: Antiplatelet agents in the perioperative period: Expert recommendations of the French Society of Anesthesiology and Intensive Care (SFAR) 2001. Summary statement. Can J Anaesth 2002;49(6):S26-S35.
110. Keating EM, Meding JB, Faris PM, Ritter MA: Long-term followup of nonmodular total knee replacements. Clin Orthop Relat Res 2002;404:34-39.
111. Chassot PG, Marcucci C, Delabays A, Spahn DR: Perioperative antiplatelet therapy. Am Fam Physician 2010;82(12): 1484-1489.
112. McEntegart A, Capell HA, Creran D, Rumley A, Woodward M, Lowe GD: Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford) 2001;40(6):640-644.
113. Wållberg-Jonsson S, Dahlén GH, Nilsson TK, Rånby M, Rantapaä-Dahlqvist S: Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol 1993;12(3):318-324.
114. Gerstein NS, Schulman PM, Gerstein WH, Petersen TR, Tawil I: Should more patients continue aspirin therapy perioperatively? Clinical impact of aspirin withdrawal syndrome. Ann Surg 2012;255(5):811-819.
115. Mont MA, Jacobs JJ, Boggio LN, et al; AAOS clinical practice guideline: Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg 2011;19(12):768-776.
116. Nguyen-Oghalai TU, Ottenbacher KJ, Caban M, Granger CV, Grecula M, Goodwin JS: The impact of rheumatoid arthritis on rehabilitation outcomes after lower extremity arthroplasty. J Clin Rheumatol 2007;13(5):247-250.
117. Stross JK, Banwell BF, Wolf FM, Becker MC: Evaluation of an education program on the management of rheumatic diseases for physical therapists. J Rheumatol 1986;13(2):374-378.
118. Vukomanovi-c A, Popovi-c Z, Durovi-c A, Krsti-c L: The effects of short-term preoperative physical therapy and education on early functional recovery of patients younger than 70 undergoing total hip arthroplasty. Vojnosanit Pregl 2008; 65(4):291-297.
119. van Heereveld HA, Laan RF, van den Hoogen FH, Malefijt MC, Novakova IR, van de Putte LB: Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement. Ann Rheum Dis 2001;60(10):974-976.
120. Niki Y, Matsumoto H, Hakozaki A, Mochizuki T, Momohara S: Rheumatoid arthritis: A risk factor for deep venous thrombosis after total knee arthroplasty? Comparative study with osteoarthritis. J Orthop Sci 2010;15(1):57-63.
121. Ravi B, Croxford R, Hollands S, et al: Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheumatol 2014;66(2):254-263.
122. Jain A, Nanchahal J, Troeberg L, Green P, Brennan F: Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis Rheum 2001;44(8):1754-1760.
123. Lakstein D, Backstein DJ, Safir O, Kosashvili Y, Gross AE: Modified trochanteric slide for complex hip arthroplasty: Clinical outcomes and complication rates. J Arthroplasty 2010; 25(3):363-368.